- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - STERLING BIOTECH
CADILA HEALTHCARE vs STERLING BIOTECH - Comparison Results
CADILA HEALTHCARE 
Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
STERLING BIOTECH
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Current Valuations
| CADILA HEALTHCARE | STERLING BIOTECH | CADILA HEALTHCARE/ STERLING BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 18.5 | -0.4 | - | View Chart |
| P/BV | x | 4.2 | 0.0 | 29,434.4% | View Chart |
| Dividend Yield | % | 1.0 | 0.0 | - |
Financials
 CADILA HEALTHCARE  STERLING BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-18 |
STERLING BIOTECH Dec-13 |
CADILA HEALTHCARE/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 558 | 11 | 5,314.3% | |
| Low | Rs | 362 | 3 | 10,632.4% | |
| Sales per share (Unadj.) | Rs | 116.3 | 26.8 | 433.8% | |
| Earnings per share (Unadj.) | Rs | 17.9 | -15.0 | -119.5% | |
| Cash flow per share (Unadj.) | Rs | 23.1 | -5.5 | -423.4% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 85.4 | 54.9 | 155.6% | |
| Shares outstanding (eoy) | m | 1,023.74 | 267.87 | 382.2% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.0 | 0.3 | 1,524.9% | |
| Avg P/E ratio | x | 25.7 | -0.5 | -5,537.4% | |
| P/CF ratio (eoy) | x | 19.9 | -1.3 | -1,562.3% | |
| Price / Book Value ratio | x | 5.4 | 0.1 | 4,250.3% | |
| Dividend payout | % | 19.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 470,664 | 1,862 | 25,281.5% | |
| No. of employees | `000 | 11.8 | 1.4 | 872.9% | |
| Total wages/salary | Rs m | 18,545 | 547 | 3,391.6% | |
| Avg. sales/employee | Rs Th | 10,072.7 | 5,303.3 | 189.9% | |
| Avg. wages/employee | Rs Th | 1,569.1 | 403.8 | 388.5% | |
| Avg. net profit/employee | Rs Th | 1,547.7 | -2,959.0 | -52.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 119,049 | 7,181 | 1,657.9% | |
| Other income | Rs m | 1,132 | 43 | 2,657.3% | |
| Total revenues | Rs m | 120,181 | 7,223 | 1,663.8% | |
| Gross profit | Rs m | 28,475 | 947 | 3,007.2% | |
| Depreciation | Rs m | 5,388 | 2,543 | 211.9% | |
| Interest | Rs m | 911 | 4,377 | 20.8% | |
| Profit before tax | Rs m | 23,308 | -5,931 | -393.0% | |
| Minority Interest | Rs m | 628 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,644 | -1,924 | -293.3% | |
| Profit after tax | Rs m | 18,292 | -4,007 | -456.6% | |
| Gross profit margin | % | 23.9 | 13.2 | 181.4% | |
| Effective tax rate | % | 24.2 | 32.4 | 74.6% | |
| Net profit margin | % | 15.4 | -55.8 | -27.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 82,005 | 14,335 | 572.1% | |
| Current liabilities | Rs m | 60,720 | 49,809 | 121.9% | |
| Net working cap to sales | % | 17.9 | -494.0 | -3.6% | |
| Current ratio | x | 1.4 | 0.3 | 469.3% | |
| Inventory Days | Days | 73 | 403 | 18.1% | |
| Debtors Days | Days | 98 | 171 | 57.6% | |
| Net fixed assets | Rs m | 83,703 | 55,432 | 151.0% | |
| Share capital | Rs m | 1,024 | 268 | 382.2% | |
| "Free" reserves | Rs m | 86,421 | 13,935 | 620.2% | |
| Net worth | Rs m | 87,445 | 14,701 | 594.8% | |
| Long term debt | Rs m | 25,551 | 9,478 | 269.6% | |
| Total assets | Rs m | 180,653 | 73,988 | 244.2% | |
| Interest coverage | x | 26.6 | -0.4 | -7,489.6% | |
| Debt to equity ratio | x | 0.3 | 0.6 | 45.3% | |
| Sales to assets ratio | x | 0.7 | 0.1 | 679.0% | |
| Return on assets | % | 10.6 | 0.5 | 2,122.2% | |
| Return on equity | % | 20.9 | -27.3 | -76.8% | |
| Return on capital | % | 22.0 | -6.4 | -342.2% | |
| Exports to sales | % | 0 | 25.9 | 0.0% | |
| Imports to sales | % | 0 | 0.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
| Imports (cif) | Rs m | NA | 12 | 0.0% | |
| Fx inflow | Rs m | 42,683 | 1,860 | 2,295.0% | |
| Fx outflow | Rs m | 11,242 | 25 | 45,166.7% | |
| Net fx | Rs m | 31,441 | 1,835 | 1,713.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,193 | 1,719 | 534.9% | |
| From Investments | Rs m | -9,737 | -3,148 | 309.3% | |
| From Financial Activity | Rs m | 515 | 1,426 | 36.1% | |
| Net Cashflow | Rs m | -29 | -3 | 852.9% | |
Share Holding
| Indian Promoters | % | 74.8 | 33.9 | 220.6% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 0.0 | - | |
| FIIs | % | 5.9 | 9.9 | 59.6% | |
| ADR/GDR | % | 0.0 | 16.9 | - | |
| Free float | % | 11.0 | 39.3 | 28.0% | |
| Shareholders | 44,069 | 21,482 | 205.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare CADILA HEALTHCARE With: SUN PHARMA DR. REDDYS LAB GSK PHARMA UNICHEM LAB MERCK LTD
Compare CADILA HEALTHCARE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)
Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.
Related Views on News
CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)
Aug 16, 2018 | Updated on Aug 16, 2018Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)
Nov 12, 2018A brand new technology and a stock that could soar with the upcoming 5G rollout.
Why the Realty Sector's Recovery Has Been Delayed(Sector Info)
Nov 15, 2018NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?
This Was a Large Cap. But Was It Safe?(Chart Of The Day)
Nov 9, 2018Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.
Investing In Small Cap Funds? Read This Before You Invest(Outside View)
Nov 19, 2018PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.
More|
| |
CADILA HEALTHCARE SHARE PRICE
Nov 21, 2018 (Close)
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE 8-QTR ANALYSIS
COMPARE CADILA HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.